How long do I have to appeal a CGRP denial?

Under ACA-standard plans you generally have 180 days from the denial to file an internal appeal, and about 4 months from the final internal denial to request external review, with an expedited track for urgent cases. Grandfathered self-insured plans are exempt from the new ACA appeals regulations, though enrollees are not entirely unprotected. ([source](https://nyhealthaccess.org/afile/170/331/)) Check the dates on your denial letter first, because the clock starts there.

Can my insurance require me to fail other migraine drugs before covering CGRP?

Often yes. That requirement is called step therapy, or "fail first," and it is one of the most common reasons a CGRP prior authorization gets denied. Many states have step-therapy override laws that let your prescriber request an exception when the required drugs are inappropriate, already failed, or unsafe for you, and the American Headache Society has argued against blanket step-therapy gating for the CGRP class. A dated record of which preventives you already tried and how each failed is what supports the override.

What is a peer-to-peer review and should I ask for one?

A peer-to-peer is a direct call between your prescriber and a physician working for your insurer, to argue the medical case after a denial. It is worth pursuing, and it goes far better when your prescriber has your documented medication-failure history in hand before the call rather than working from memory or a thin chart.

What is external review and is the decision binding?

External review sends your case to an independent organization outside your insurer after you exhaust internal appeals. Under ACA-standard plans the external reviewer's decision binds the plan, meaning if they rule in your favor the insurer must cover the drug. Self-funded ERISA plans must respond within 30 days for pre-service claims and 60 days for post-service claims. ([source](https://www.counterforcehealth.org/post/erisa-appeal-rights-the-hidden-advantage-in-self-funded-plan-denials/))

What to do when your insurance denies CGRP coverage

Article · 4 min read

A CGRP denial is a first move, not a verdict.

Insurers deny CGRP coverage counting on you to quit. Here is the appeal ladder, stage by stage, and the documentation that overturns a 'not medically necessary.'

The letter that decides for you

The envelope carries your plan's logo, and the sentence inside reads "not medically necessary." You have already failed the triptan that stopped working after two years, the amitriptyline that flattened you into a fog, and the beta-blocker your neurologist tried before writing the CGRP script. Someone in a claims queue who has never seen your headache calendar decided the drug your headache specialist chose is not warranted. The residual photophobia is still there behind your eyes as you read it. For most people, the word "denied" lands as a full stop.

Designed attrition

A first-pass CGRP denial is rarely a physician's judgment about your case. It is a gate, and the gate is built to make you go away. Call it designed attrition: the plan denies, a large share of patients read "denied" as "over," and the plan keeps the money it would have spent on eptinezumab or rimegepant. The single most expensive misread in the whole process is treating the first no as a verdict. It is a form. Forms get answered.

Why 'not medically necessary' rarely means what it says

The phrase sounds like a doctor weighed your chart and disagreed. In practice, first denials on the CGRP class are usually driven by a step-therapy rule (the plan wants you to fail two or three cheaper preventives first) or by a prior-authorization form that was missing a specific field. Automated adjudication flags a rule mismatch; a human may never have read your history at all. That distinction matters, because a decision made by a rule is beaten by satisfying the rule on paper, not by pleading your case over the phone. Once you stop reading the denial as a personal rejection and start reading it as a checklist you have not yet completed, every next step becomes mechanical.

What the appeal numbers actually show

The uncomfortable pattern in the data is that the system runs on people not appealing. Analyses of Affordable Care Act marketplace claims have found that patients appeal only a tiny fraction of denied in-network claims, and that a meaningful share of the appeals that do get filed are overturned. The American Headache Society has also pushed back on blanket step-therapy requirements for CGRP therapies, arguing the class should be accessible without forcing failure on older drugs first for appropriate patients. The takeaway is not that appeals are easy. It is that the denial rate and the give-up rate are two different numbers, and the second one is the one insurers are counting on.

Consumers appealed only 1% of denied in-network claims to their insurer, per KFF analysis of 2023 ACA Marketplace data. ([source](https://www.healthcaredive.com/news/aca-plans-denied-one-fifth-of-in-network-claims-2023-kff/738389/))

of denied claims are ever appealed by patientsKFF, Some CGRP coverage authorizations may last up to a year, after which a reauthorization process evaluates clinical benefit. ([source](https://www.ajmc.com/view/criteria-for-coverage-of-cgrp-antagonists-in-migraine))

Appeals of health insurance claim denials resulted in overturned decisions between 30% and 78% of the time when reaching independent review. ([source](https://acdis.org/articles/news-insurance-denials-overturned-high-rates-independent-review-experts-analysis-says))

of appealed denials get overturnedA 2023 KFF survey found 16% of all insured adults experienced prior authorization problems in the past year. ([source](https://www.kff.org/affordable-care-act/consumer-problems-with-prior-authorization-evidence-from-kff-survey/))

Step therapy is required in 72% of commercial plans for CGRP monoclonal antibodies, which list at $8,100–$9,400 annually in the U.S. ([source](https://www.mordorintelligence.com/industry-reports/migraine-therapeutics-market))

of plans gate the CGRP class behind step therapy or PAPatients must file a health insurance internal appeal within 180 days (6 months) of receiving notice that their claim was denied. ([source](https://www.cms.gov/cciio/resources/fact-sheets-and-faqs/appeals06152012a))

The ladder, one rung at a time

Picture the standard commercial sequence. Your neurologist submits the prior authorization; the plan's system checks it against a step-therapy rule and returns a denial. That is rung one, and it is where most people stop. Rung two is the internal appeal, filed in writing, citing the exact policy criterion the plan claims you missed. Rung three is the peer-to-peer, where your prescriber talks directly to the plan's reviewing physician, a call that goes far better when your prescriber walks in holding a dated record of which preventives you tried and how each one failed. Rung four is external review, where an independent organization outside your insurer looks at the file, and under ACA-standard plans that decision binds the plan. Most denials never reach rung four because most people never climb past rung one.

The commercial appeal ladder under ACA-standard, non-grandfathered plans. Self-funded ERISA and grandfathered plans vary. External review decisions by MAXIMUS are final and binding; standard reviews are decided no later than 45 days after request received. ([source](https://www.cms.gov/cciio/programs-and-initiatives/consumer-support-and-information/csg-ext-appeals-facts))
Stage	What it looks like	What most people do	What works
Prior auth	Prescriber submits; the system checks it against a step-therapy rule	Wait and hope	Front-load the file: prior preventives, dates, outcomes
First denial	"Not medically necessary" or "step therapy not met"	Pay cash or stop the drug	File the internal appeal in writing, quote the exact policy criterion
Peer-to-peer	Your prescriber calls the plan's reviewing physician	Skip it	Hand your prescriber your documented failure history before the call
External review	An independent organization outside the plan rules on the file	Never reach it	Request it in writing; the decision binds the plan

The deadline is the real gate

Under ACA-standard plans you typically have 180 days from a denial to file the internal appeal, and 4 months from the final internal denial to request external review; urgent cases can use an expedited track. Expedited external reviews must be decided within 72 hours after the IRO receives the request. ([source](https://www.law.cornell.edu/cfr/text/45/147.136)) Miss the window and the rung closes for good.

The appeal is won in the records

If the denial is a checklist rather than a judgment, the thing that moves it is evidence, not eloquence. Nobody at the plan is persuaded by how much the migraines hurt. They are moved by a dated, legible record: how many headache days a month, which preventives you took, at what dose, for how long, and exactly how each one failed or what side effect stopped it. That record is what turns a peer-to-peer from a two-minute brush-off into a documented case, and it is what an external reviewer reads. The patients who win are almost always the ones who could produce six months of history without reconstructing it from memory.

The plan is not moved by how much it hurt. It is moved by a dated record of what you already tried.

The record you can't rebuild from memory

Here is where the appeal quietly breaks for most people. Reconstructing six months of headache days, medication trials, and postdrome recovery time from memory is hard for anyone, and it is close to impossible mid-cycle, when the brain fog and residual photophobia are the whole problem. A tracker that stops at the headache leaves you nothing to hand the reviewer. A continuous timeline that logs every attack, every medication trial and its outcome, and the 24 to 72 hours of postdrome after the pain lifts is, almost by accident, the exact shape of evidence a prior authorization and an appeal ask for. That is the record Postdrome keeps, on your device, and it is why the CGRP Prior-Auth Letter Builder can turn it into the written internal appeal the ladder needs at rung two.

What we're watching

The rules are moving. State step-therapy reform laws keep expanding the exceptions patients can claim, gold-carding programs are starting to exempt high-approval prescribers from prior auth entirely, and federal prior-authorization reform is tightening turnaround requirements on plans. CMS-0057-F requires impacted payers to implement certain provisions by January 1, 2026; a new proposed rule sets an October 1, 2027 compliance date. ([source](https://www.cms.gov/initiatives/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-prior-authorization-final-rule-cms-0057-f)) None of it makes the first denial go away yet. All of it makes the case for keeping the record that gets you past it.

Keep a headache-day record your appeal can actually use. Postdrome logs every attack, every medication trial and how it failed, and the postdrome days most trackers ignore, on your device, one lifetime price. Bring the timeline your prescriber needs for the peer-to-peer.

Postdrome was built by people who watched migraines wreck the people they love, and watched good tracking apps stop at the headache and leave nothing for the parts that matter later: the postdrome days, and the paper trail an insurer demands. It logs every attack and every medication trial on your device, one lifetime price, no subscription and no data sold. When your neurologist walks into the peer-to-peer, the history is already there.

Get Postdrome